CIK 0001785173
ETNB 89bio, Inc.
Insider trading from SEC Form 4. Last filing Nov 3, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
14
with a Form 4 at this company
Signals
Open-market buys and sells at 89bio, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 5Weak | Quoc Le-Nguyen See Remarks sell | $115k 10,461 shares | -3% | - | |
| 4Weak | Quoc Le-Nguyen See Remarks sell | $91k 15,329 shares | -4% | - | |
| 54Moderate | Ra Capital Management, L.p. director, owner buy | $50M 5,714,285 shares | +41% | - | |
| 48Moderate | Charles McWherter director buy | $100k 15,000 shares | +150% | - | |
| 3Weak | Quoc Le-Nguyen See Remarks sell | $71k 10,963 shares | -4% | - | |
| 44Moderate | Rohan Palekar Chief Executive Officer buy | $39k 5,000 shares | +1% | - | |
| 40Moderate | Charles McWherter director buy | $80k 10,000 shares | - | - | |
| 42Moderate | Rohan Palekar Chief Executive Officer buy | $84k 10,000 shares | +2% | - | |
| 13Weak | Quoc Le-Nguyen See Remarks sell | $227k 27,955 shares | -13% | - |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 30, 2025 | Ra Capital Management, L.p. director, owner | DDisposition to issuer Common Stockindirect: See Footnotes | -19,554,319 | - | - | 0 | Nov 3, 2025 |
| Oct 30, 2025 | Ra Capital Management, L.p. director, owner | DDisposition to issuer Common Stockindirect: See Footnotes | -335,364 | - | - | 0 | Nov 3, 2025 |
| Oct 30, 2025 | Ra Capital Management, L.p. director, owner | DDisposition to issuer Pre-Funded Warrants (Right to Buy)derivativeindirect: See footnotes | -4,331,081 | $0.00 | $0 | 0 | Nov 3, 2025 |
| Oct 30, 2025 | Ra Capital Management, L.p. director, owner | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: See footnotes | -7,000 | $0.00 | $0 | 0 | Nov 3, 2025 |
| Oct 30, 2025 | Ra Capital Management, L.p. director, owner | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: See footnotes | -7,000 | $0.00 | $0 | 0 | Nov 3, 2025 |
| Oct 30, 2025 | Ra Capital Management, L.p. director, owner | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: See footnotes | -12,500 | $0.00 | $0 | 0 | Nov 3, 2025 |
| Oct 30, 2025 | Ra Capital Management, L.p. director, owner | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: See footnotes | -25,000 | $0.00 | $0 | 0 | Nov 3, 2025 |
| Oct 30, 2025 | Ra Capital Management, L.p. director, owner | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: See footnotes | -27,400 | $0.00 | $0 | 0 | Nov 3, 2025 |
| Oct 30, 2025 | Ra Capital Management, L.p. director, owner | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: See footnotes | -45,150 | $0.00 | $0 | 0 | Nov 3, 2025 |
| Oct 30, 2025 | Ra Capital Management, L.p. director, owner | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: See footnotes | -56,400 | $0.00 | $0 | 0 | Nov 3, 2025 |
| Oct 30, 2025 | Michael R Hayden director | UTender of shares Common Stock | -80,904 | - | - | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Francis Willard Sarena Chief Operating Officer | UTender of shares Common Stock | -75,310 | - | - | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Edward Morrow Atkinson III director | DDisposition to issuer Stock Option (Right to Buy)derivative | -20,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Martin Babler director | DDisposition to issuer Stock Option (Right to Buy)derivative | -67,700 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Ryan Martins Chief Financial Officer | AGrant or award Common Stock | +35,000 | $0.00 | $0 | 374,295 | Oct 30, 2025 |
| Oct 30, 2025 | Lota S. Zoth director | DDisposition to issuer Stock Option (Right to Buy)derivative | -20,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Charles McWherter director | UTender of shares Common Stock | -25,000 | - | - | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Quoc Le-Nguyen See Remarks | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 351,684 | Oct 30, 2025 |
| Oct 30, 2025 | Derek DiRocco director | DDisposition to issuer Stock Option (Right to Buy)derivative | -7,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Steven Altschuler director | DDisposition to issuer Stock Option (Right to Buy)derivative | -40,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Harry H Mansbach Chief Medical Officer | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 352,656 | Oct 30, 2025 |
| Oct 30, 2025 | Rohan Palekar Chief Executive Officer | AGrant or award Common Stock | +125,000 | $0.00 | $0 | 934,273 | Oct 30, 2025 |
| Oct 30, 2025 | Kathleen Laporte director | DDisposition to issuer Stock Option (Right to Buy)derivative | -25,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Ryan Martins Chief Financial Officer | UTender of shares Common Stock | -374,295 | - | - | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Francis Willard Sarena Chief Operating Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -350,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Lota S. Zoth director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,500 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Michael R Hayden director | UTender of shares Common Stockindirect: See footnote | -103,978 | - | - | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Edward Morrow Atkinson III director | DDisposition to issuer Stock Option (Right to Buy)derivative | -27,400 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Rohan Palekar Chief Executive Officer | UTender of shares Common Stock | -934,273 | - | - | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Charles McWherter director | DDisposition to issuer Stock Option (Right to Buy)derivative | -67,700 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Quoc Le-Nguyen See Remarks | UTender of shares Common Stock | -351,684 | - | - | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Kathleen Laporte director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,500 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Martin Babler director | DDisposition to issuer Stock Option (Right to Buy)derivative | -56,400 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Harry H Mansbach Chief Medical Officer | UTender of shares Common Stock | -352,656 | - | - | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Steven Altschuler director | DDisposition to issuer Stock Option (Right to Buy)derivative | -7,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Derek DiRocco director | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: See footnote | -7,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Derek DiRocco director | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: See footnote | -12,500 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Edward Morrow Atkinson III director | DDisposition to issuer Stock Option (Right to Buy)derivative | -45,150 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Kathleen Laporte director | DDisposition to issuer Stock Option (Right to Buy)derivative | -27,400 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Lota S. Zoth director | DDisposition to issuer Stock Option (Right to Buy)derivative | -25,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Charles McWherter director | DDisposition to issuer Stock Option (Right to Buy)derivative | -56,400 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Quoc Le-Nguyen See Remarks | UTender of shares Common Stockindirect: By Spouse | -13,694 | - | - | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Rohan Palekar Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -120,231 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Ryan Martins Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -47,500 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Michael R Hayden director | UTender of shares Common Stockindirect: See footnote | -61,538 | - | - | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Francis Willard Sarena Chief Operating Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -215,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Harry H Mansbach Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -98,204 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Steven Altschuler director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,500 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Ryan Martins Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -57,500 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Lota S. Zoth director | DDisposition to issuer Stock Option (Right to Buy)derivative | -27,400 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Derek DiRocco director | DDisposition to issuer Stock Option (Right to Buy)derivative | -25,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Michael R Hayden director | DDisposition to issuer Stock Option (Right to Buy)derivative | -27,647 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Harry H Mansbach Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -39,037 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Kathleen Laporte director | DDisposition to issuer Stock Option (Right to Buy)derivative | -45,150 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Edward Morrow Atkinson III director | DDisposition to issuer Stock Option (Right to Buy)derivative | -56,400 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Rohan Palekar Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -132,242 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Quoc Le-Nguyen See Remarks | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,063 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Steven Altschuler director | DDisposition to issuer Stock Option (Right to Buy)derivative | -25,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Ryan Martins Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -48,102 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Derek DiRocco director | DDisposition to issuer Stock Option (Right to Buy)derivative | -27,400 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Michael R Hayden director | DDisposition to issuer Stock Option (Right to Buy)derivative | -2,933 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Lota S. Zoth director | DDisposition to issuer Stock Option (Right to Buy)derivative | -45,150 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Harry H Mansbach Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -45,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Kathleen Laporte director | DDisposition to issuer Stock Option (Right to Buy)derivative | -56,400 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Rohan Palekar Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -170,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Quoc Le-Nguyen See Remarks | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,312 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Steven Altschuler director | DDisposition to issuer Stock Option (Right to Buy)derivative | -27,400 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Steven Altschuler director | DDisposition to issuer Stock Option (Right to Buy)derivative | -45,150 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Ryan Martins Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -110,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Derek DiRocco director | DDisposition to issuer Stock Option (Right to Buy)derivative | -45,150 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Michael R Hayden director | DDisposition to issuer Stock Option (Right to Buy)derivative | -22,730 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Lota S. Zoth director | DDisposition to issuer Stock Option (Right to Buy)derivative | -56,400 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Harry H Mansbach Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -67,500 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Rohan Palekar Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -203,750 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Quoc Le-Nguyen See Remarks | DDisposition to issuer Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Steven Altschuler director | DDisposition to issuer Stock Option (Right to Buy)derivative | -56,400 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Ryan Martins Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -175,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Michael R Hayden director | DDisposition to issuer Stock Option (Right to Buy)derivative | -7,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Derek DiRocco director | DDisposition to issuer Stock Option (Right to Buy)derivative | -56,400 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Rohan Palekar Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -220,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Harry H Mansbach Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -70,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Quoc Le-Nguyen See Remarks | DDisposition to issuer Stock Option (Right to Buy)derivative | -67,500 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Harry H Mansbach Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -120,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Ryan Martins Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -300,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Michael R Hayden director | DDisposition to issuer Stock Option (Right to Buy)derivative | -7,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Rohan Palekar Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -300,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Quoc Le-Nguyen See Remarks | DDisposition to issuer Stock Option (Right to Buy)derivative | -70,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Harry H Mansbach Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -195,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Michael R Hayden director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,500 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Rohan Palekar Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -605,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Quoc Le-Nguyen See Remarks | DDisposition to issuer Stock Option (Right to Buy)derivative | -120,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Quoc Le-Nguyen See Remarks | DDisposition to issuer Stock Option (Right to Buy)derivative | -195,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Michael R Hayden director | DDisposition to issuer Stock Option (Right to Buy)derivative | -25,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Harry H Mansbach Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -320,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Rohan Palekar Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -848,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Quoc Le-Nguyen See Remarks | DDisposition to issuer Stock Option (Right to Buy)derivative | -320,000 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Michael R Hayden director | DDisposition to issuer Stock Option (Right to Buy)derivative | -27,400 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Quoc Le-Nguyen See Remarks | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: By Spouse | -26,400 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Michael R Hayden director | DDisposition to issuer Stock Option (Right to Buy)derivative | -45,150 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 30, 2025 | Quoc Le-Nguyen See Remarks | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: By Spouse | -17,500 | $0.00 | $0 | 0 | Oct 30, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Steven Altschulerdirector
- Edward Morrow Atkinson IIIdirector, officer
- Martin Bablerdirector, ceo, president, chair, officer
- Derek DiRoccodirector
- Michael R Haydendirector
- Kathleen Laportedirector
- Quoc Le-NguyenSee Remarks
- Harry H MansbachChief Medical Officer
- Ryan MartinsChief Financial Officer
- Charles McWherterdirector
- Rohan PalekarChief Executive Officer
- Ra Capital Management, L.p.owner, director
- Francis Willard SarenaChief Operating Officer
- Lota S. Zothdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.